Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study

NCT00514020 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT00514020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00514020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
February 28, 2011
Enrollment
33 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer